Abstract
Previously, we demonstrated that the addition of subcutaneous Dupilumab to intranasal corticosteroid has additive beneficial effects for uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Clinical observations led us to believe that the addition of intravenous Reslizumab, an interleukin-5 antagonist monoclonal antibody (IgG4 kappa), may provide additional efficacy in sub optimally controlled CRSwNP despite daily use of intranasal glucocorticosteroid (INCS) Mometasone furoate with interval necessity of systemic corticosteroids for breakthrough relief.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
